MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 186.16% ano a ano.
Virada para Lucro
O desempenho da empresa passou a ser positivo, com lucro líquido anual mais recente de US$ 27.59M.%!(EXTRA int=2)
Avaliação Justa
O PE mais recente da empresa é 47.17, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 184.37M ações, um aumento de 1.19% em relação ao trimestre anterior.
Mantido por The Vanguard
O Super Investidor The Vanguard possui 18.10M ações desta empresa.